DNASE2B

Across TCGA pan-cancer cohorts, DNASE2B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DNASE2B data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DNASE2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNASE2B expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

LUAD, KIRC, and LGG are the cancer types where DNASE2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.237	0.790	<.001	16	view →
KIRC	OS	Median	All	0.057	0.881	<.001	12	view →
LGG	OS	Median	All	0.238	0.810	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.121	0.415	.042	3	view →
LUSC	DFS	Median	All	0.831	0.366	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DNASE2B–LUAD (OS)

Open the LUAD breakdown →